Holen Sie sich die Stockscreener-App
13.17
0.08%
-0.010
Handel nachbörslich:
12.94
-0.23
-1.75%
Schlusskurs vom Vortag:
$13.18
Offen:
$13.15
24-Stunden-Volumen:
773.91K
Relative Volume:
1.20
Marktkapitalisierung:
$892.24M
Einnahmen:
$568.09M
Nettoeinkommen (Verlust:
$27.27M
KGV:
40.20
EPS:
0.3276
Netto-Cashflow:
$71.41M
1W Leistung:
+11.61%
1M Leistung:
+39.51%
6M Leistung:
+66.08%
1J Leistung:
+101.99%
1-Tages-Spanne:
$12.43
$13.25
1-Wochen-Bereich:
$11.90
$13.55
52-Wochen-Spanne:
$5.81
$13.55
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
13.17 | 843.46M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | CJS Securities | Market Outperform |
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Bioventus (NASDAQ:BVS) Hits New 12-Month HighStill a Buy? - MarketBeat
Eversept Partners LP Lowers Stake in Bioventus Inc. $BVS - MarketBeat
315,018 Shares in Bioventus Inc. $BVS Bought by Engine Capital Management LP - MarketBeat
BlackRock (BVS) discloses 3.4M-share, 5.02% passive stake in Bioventus - Stock Titan
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
BVS|Bioventus Inc|Price:12.460|Chg%:+0.660 - TradingKey
Bioventus Inc (BVS) Balance Sheet - TradingKey
Bioventus Inc (BVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioventus Inc (BVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioventus Inc (BVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BVS|Bioventus Inc|Price:12.960|Chg%:+0.510 - TradingKey
TradingKey - TradingKey
Bioventus, Inc. (BVS) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? - Yahoo Finance
161,926 Shares in Bioventus Inc. $BVS Acquired by Fifth Third Bancorp - MarketBeat
Bioventus Inc (BVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Understanding the Setup: (BVS) and Scalable Risk - Stock Traders Daily
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioventus (BVS) Upgraded to Buy: Here's Why - Yahoo Finance
Should Value Investors Buy Bioventus (BVS) Stock? - Yahoo Finance
Bioventus (BVS) Q4 2025 earnings summary - Quartr
Bioventus (BVS) Proxy filing Summary - Quartr
Bioventus (BVS) Q3 2024 earnings summary - Quartr
Bioventus (BVS) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
Bioventus (BVS) Q2 2024 earnings summary - Quartr
Bioventus (BVS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Bioventus (BVS) Q1 2026 earnings summary - Quartr
Bioventus (BVS) Corporate presentation Summary - Quartr
Bioventus, Inc. (BVS) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
A Look at Bioventus Inc (BVS) After 4.1% Decline -- GF Value $6. - GuruFocus
Bioventus Down Nearly 9%, On Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Bioventus Inc. (BVS) Slides 1.93% as Selling Pressure Tests Near-Term Support LevelsBullish Percent Index - dars.gov.et
Bioventus (NASDAQ:BVS) Reaches New 12-Month HighHere's Why - MarketBeat
Hillsdale Investment Management Inc. Raises Stake in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Bioventus Q1 2026 Earnings: EPS Beat Exceeds Estimates, But Stock SlipsPositive Surprise Momentum - dars.gov.et
Bioventus Slips Amid Selling Pressure: Key Levels to Watch for BVSFair Value Gap - dars.gov.et
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks - Yahoo Finance
Bioventus, Inc. Class A Actuals & Estimates (LSX:A2APNA) - TradingView
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice - Yahoo Finance
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $16 - Moomoo
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know - Yahoo Finance
Bioventus Deadline Alert - TMX Newsfile
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), Bioventus (BVS) and Crinetics Pharmaceuticals (CRNX) - The Globe and Mail
A2APNA Forecast — Price Target — Prediction for 2027 - TradingView
A2APNA Stock Price and Chart — LSX:A2APNA - TradingView
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade) (NASDAQ:BVS) - Seeking Alpha
BioventusTargeting Earnings Growth Outpacing Revenue Growth In 2026 - RTTNews
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zacks.com featured highlights include First Advantage, Bioventus and Ooma - Yahoo Finance
Bioventus stock surges on favorable 2027 outpat... - Pluang
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioventus Inc-Aktie (BVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SUTTER MARTIN P | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
117,523 |
| STALNECKER SUSAN M | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
138,239 |
| NOHRA GUY P | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
148,892 |
| NEELS GUIDO J | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
117,523 |
| McMurry-Heath Michelle | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
77,279 |
| Ladone Mary Kay | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
111,263 |
| HAWKINS WILLIAM A | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
39,789 |
0 |
297,640 |
| Cowdy Philip G. | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
43,982 |
| Beyer Pat | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
108,718 |
| Singleton Mark Leonard | SVP & CFO |
Apr 10 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
182,981 |
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):